Answers are grounded in this paper and cite their sources.
The treatment of uveitis is undergoing significant change as a result of the development of new therapeutic approaches, of which the biologic agents form a major part. These targeted therapies have shown great promise for the treatment of refractory disease and some have now undergone systematic evaluation through prospective clinical trials, unlike many of their predecessor drugs.
No takes yet. Share an insight, caveat, or question.
Simon Taylor (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: